The Spanish research group presents an invention focused on the preparation of active nanoconjugates against advanced prostate cancer and to prevent metastasis.
The formation of the nanoconjugates is carried out by mixing in solution, preferably aqueous in the presence or absence of buffer, the dendritic molecules, and the corresponding peptides.
These systems are formed by dendritic molecules (dendrimers and dendrons) and neuropeptides. Preferably, the dendritic macromolecules are of carbosilane structure, mainly with cationic functions in the periphery, and the neuropeptides are of the glucagon/secretin family, mainly VIP, GHRH, and PACAP. These nanoconjugates are formed by combining the dendritic molecule and the corresponding peptide in the necessary proportion.
The present invention also relates to the biomedical uses of the peptide / dendritic molecule combinations.
Preferably this invention is for the development of drugs for the treatment of prostate cancer. However, other types of cancers are not excluded. Examples of pharmaceutical preparations include any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels, solutions, suspensions or emulsions) for oral, nasal, topical or parenteral administration.
The research group seeks for companies and research institutions from the Biomedicine, Pharmaceutical and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.